The development of molecularly targeted therapeutics, such as tyrosine kinase inhibitors (TKI) directed against epidermal growth factor receptor (EGFR) mutations (e.g., erlotinib, gefibinib and osimertinib) and anaplastic large-cell lymphoma kinase (ALK) rearrangement (e.g., crizotinib, certinib, alectinib and brigatinib), has improved outcomes of lung cancer patients with these mutation [4,5,6,7]. This evidence concerns the gene ALK and lung carcinoma.